Regeneron Pharmaceuticals, Inc. (REGN)
USD 564.26
(-1.6%)
USD 564.26
(-1.6%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 3.95 Billion USD | -8.87% |
| 2022 | 4.33 Billion USD | -46.28% |
| 2021 | 8.07 Billion USD | 129.86% |
| 2020 | 3.51 Billion USD | 66.05% |
| 2019 | 2.11 Billion USD | -13.44% |
| 2018 | 2.44 Billion USD | 103.95% |
| 2017 | 1.19 Billion USD | 33.83% |
| 2016 | 895.52 Million USD | 40.79% |
| 2015 | 636.05 Million USD | 82.74% |
| 2014 | 348.07 Million USD | -17.98% |
| 2013 | 424.36 Million USD | -43.44% |
| 2012 | 750.26 Million USD | 438.32% |
| 2011 | -221.76 Million USD | -112.28% |
| 2010 | -104.46 Million USD | -54.01% |
| 2009 | -67.83 Million USD | 17.99% |
| 2008 | -82.71 Million USD | 21.68% |
| 2007 | -105.6 Million USD | -3.19% |
| 2006 | -102.33 Million USD | -7.22% |
| 2005 | -95.44 Million USD | -328.89% |
| 2004 | 41.69 Million USD | 138.8% |
| 2003 | -107.45 Million USD | 13.6% |
| 2002 | -124.37 Million USD | -63.27% |
| 2001 | -76.18 Million USD | -228.15% |
| 2000 | -23.21 Million USD | -0.5% |
| 1999 | -23.1 Million USD | -168.6% |
| 1998 | -8.6 Million USD | 25.86% |
| 1997 | -11.6 Million USD | 64.2% |
| 1996 | -32.4 Million USD | -37.87% |
| 1995 | -23.5 Million USD | 23.45% |
| 1994 | -30.7 Million USD | 23.06% |
| 1993 | -39.9 Million USD | -108.9% |
| 1992 | -19.1 Million USD | -324.44% |
| 1991 | -4.5 Million USD | -36.36% |
| 1990 | -3.3 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 1.34 Billion USD | -6.4% |
| 2024 Q1 | 722 Million USD | -37.74% |
| 2024 Q2 | 1.43 Billion USD | 98.38% |
| 2023 Q3 | 1 Billion USD | 4.07% |
| 2023 Q4 | 1.15 Billion USD | 15.06% |
| 2023 FY | 3.95 Billion USD | -8.87% |
| 2023 Q1 | 817.8 Million USD | -31.68% |
| 2023 Q2 | 968.4 Million USD | 18.42% |
| 2022 Q2 | 852.1 Million USD | -12.47% |
| 2022 Q4 | 1.19 Billion USD | -9.01% |
| 2022 FY | 4.33 Billion USD | -46.28% |
| 2022 Q1 | 973.5 Million USD | -56.33% |
| 2022 Q3 | 1.31 Billion USD | 54.41% |
| 2021 FY | 8.07 Billion USD | 129.86% |
| 2021 Q2 | 3.09 Billion USD | 177.88% |
| 2021 Q1 | 1.11 Billion USD | -2.96% |
| 2021 Q4 | 2.22 Billion USD | 36.56% |
| 2021 Q3 | 1.63 Billion USD | -47.33% |
| 2020 FY | 3.51 Billion USD | 66.05% |
| 2020 Q4 | 1.14 Billion USD | 36.47% |
| 2020 Q3 | 842.1 Million USD | -6.15% |
| 2020 Q2 | 897.3 Million USD | 43.66% |
| 2020 Q1 | 624.6 Million USD | -21.14% |
| 2019 Q4 | 792 Million USD | 18.28% |
| 2019 FY | 2.11 Billion USD | -13.44% |
| 2019 Q1 | 461.1 Million USD | -43.8% |
| 2019 Q2 | 193.1 Million USD | -58.12% |
| 2019 Q3 | 669.6 Million USD | 246.76% |
| 2018 Q3 | 594.65 Million USD | 7.84% |
| 2018 Q2 | 551.41 Million USD | 15.36% |
| 2018 Q1 | 477.98 Million USD | 175.46% |
| 2018 FY | 2.44 Billion USD | 103.95% |
| 2018 Q4 | 820.4 Million USD | 37.96% |
| 2017 Q3 | 388.31 Million USD | 0.15% |
| 2017 FY | 1.19 Billion USD | 33.83% |
| 2017 Q4 | 173.51 Million USD | -55.32% |
| 2017 Q1 | 248.93 Million USD | -1.65% |
| 2017 Q2 | 387.74 Million USD | 55.76% |
| 2016 Q2 | 196.21 Million USD | 18.39% |
| 2016 Q3 | 264.8 Million USD | 34.95% |
| 2016 FY | 895.52 Million USD | 40.79% |
| 2016 Q1 | 165.73 Million USD | 6.93% |
| 2016 Q4 | 253.11 Million USD | -4.41% |
| 2015 Q3 | 210.39 Million USD | 8.09% |
| 2015 FY | 636.05 Million USD | 82.74% |
| 2015 Q2 | 194.64 Million USD | 156.04% |
| 2015 Q4 | 154.99 Million USD | -26.33% |
| 2015 Q1 | 76.02 Million USD | -31.0% |
| 2014 FY | 348.07 Million USD | -17.98% |
| 2014 Q3 | 79.72 Million USD | -14.03% |
| 2014 Q2 | 92.73 Million USD | 41.7% |
| 2014 Q1 | 65.44 Million USD | -32.4% |
| 2014 Q4 | 110.17 Million USD | 38.2% |
| 2013 Q2 | 87.37 Million USD | -11.63% |
| 2013 Q3 | 141.3 Million USD | 61.72% |
| 2013 FY | 424.36 Million USD | -43.44% |
| 2013 Q4 | 96.8 Million USD | -31.49% |
| 2013 Q1 | 98.87 Million USD | -78.98% |
| 2012 FY | 750.26 Million USD | 438.32% |
| 2012 Q1 | 11.65 Million USD | 121.8% |
| 2012 Q2 | 76.74 Million USD | 558.68% |
| 2012 Q3 | 191.46 Million USD | 149.49% |
| 2012 Q4 | 470.4 Million USD | 145.68% |
| 2011 Q1 | -43.44 Million USD | -197.64% |
| 2011 FY | -221.76 Million USD | -112.28% |
| 2011 Q4 | -53.44 Million USD | 14.31% |
| 2011 Q3 | -62.36 Million USD | 0.22% |
| 2011 Q2 | -62.5 Million USD | -43.86% |
| 2010 Q3 | -33.87 Million USD | -32.98% |
| 2010 Q4 | -14.59 Million USD | 56.91% |
| 2010 FY | -104.46 Million USD | -54.01% |
| 2010 Q1 | -30.52 Million USD | 16.35% |
| 2010 Q2 | -25.47 Million USD | 16.54% |
| 2009 Q1 | -17.48 Million USD | 44.54% |
| 2009 Q2 | -14.93 Million USD | 14.55% |
| 2009 Q3 | -1.01 Million USD | 93.21% |
| 2009 Q4 | -36.48 Million USD | -3494.98% |
| 2009 FY | -67.83 Million USD | 17.99% |
| 2008 Q3 | -21.11 Million USD | -14.39% |
| 2008 Q4 | -31.51 Million USD | -49.27% |
| 2008 FY | -82.71 Million USD | 21.68% |
| 2008 Q1 | -11.61 Million USD | 11.12% |
| 2008 Q2 | -18.45 Million USD | -58.88% |
| 2007 FY | -105.6 Million USD | -3.19% |
| 2007 Q4 | -13.07 Million USD | 63.53% |
| 2007 Q3 | -35.83 Million USD | -33.85% |
| 2007 Q2 | -26.77 Million USD | 10.51% |
| 2007 Q1 | -29.91 Million USD | 3.4% |
| 2006 Q3 | -27.41 Million USD | -16.26% |
| 2006 Q2 | -23.57 Million USD | -15.68% |
| 2006 Q1 | -20.38 Million USD | 31.32% |
| 2006 FY | -102.33 Million USD | -7.22% |
| 2006 Q4 | -30.97 Million USD | -12.99% |
| 2005 Q3 | -34.65 Million USD | -28.35% |
| 2005 Q1 | -4.12 Million USD | -247.67% |
| 2005 Q2 | -26.99 Million USD | -554.84% |
| 2005 FY | -95.44 Million USD | -328.89% |
| 2005 Q4 | -29.67 Million USD | 14.37% |
| 2004 Q3 | -11.07 Million USD | 23.87% |
| 2004 FY | 41.69 Million USD | 138.8% |
| 2004 Q1 | 64.53 Million USD | 433.03% |
| 2004 Q2 | -14.54 Million USD | -122.55% |
| 2004 Q4 | 2.79 Million USD | 125.21% |
| 2003 Q1 | -30.11 Million USD | 15.64% |
| 2003 FY | -107.45 Million USD | 13.6% |
| 2003 Q4 | -19.37 Million USD | 29.28% |
| 2003 Q3 | -27.4 Million USD | 4.65% |
| 2003 Q2 | -28.73 Million USD | 4.56% |
| 2002 Q1 | -25.44 Million USD | 10.34% |
| 2002 FY | -124.37 Million USD | -63.27% |
| 2002 Q2 | -30.42 Million USD | -19.56% |
| 2002 Q3 | -32.81 Million USD | -7.87% |
| 2002 Q4 | -35.69 Million USD | -8.77% |
| 2001 Q2 | -14.83 Million USD | -13.78% |
| 2001 FY | -76.18 Million USD | -228.15% |
| 2001 Q4 | -28.37 Million USD | -42.38% |
| 2001 Q3 | -19.93 Million USD | -34.36% |
| 2001 Q1 | -13.03 Million USD | -33.86% |
| 2000 FY | -23.21 Million USD | -0.5% |
| 2000 Q1 | -7.31 Million USD | -422.71% |
| 2000 Q2 | -2.94 Million USD | 59.73% |
| 2000 Q3 | -3.21 Million USD | -8.96% |
| 2000 Q4 | -9.73 Million USD | -203.3% |
| 1999 Q3 | -4.9 Million USD | 37.18% |
| 1999 Q4 | -1.4 Million USD | 71.43% |
| 1999 FY | -23.1 Million USD | -168.6% |
| 1999 Q1 | -8.9 Million USD | -61.82% |
| 1999 Q2 | -7.8 Million USD | 12.36% |
| 1998 Q3 | -1.4 Million USD | -166.67% |
| 1998 Q4 | -5.5 Million USD | -292.86% |
| 1998 FY | -8.6 Million USD | 25.86% |
| 1998 Q1 | -3.8 Million USD | -860.0% |
| 1998 Q2 | 2.1 Million USD | 155.26% |
| 1997 Q2 | -4.3 Million USD | 27.12% |
| 1997 FY | -11.6 Million USD | 64.2% |
| 1997 Q4 | 500 Thousand USD | 126.32% |
| 1997 Q3 | -1.9 Million USD | 55.81% |
| 1997 Q1 | -5.9 Million USD | 27.16% |
| 1996 FY | -32.4 Million USD | -37.87% |
| 1996 Q4 | -8.1 Million USD | 8.99% |
| 1996 Q3 | -8.9 Million USD | -17.11% |
| 1996 Q2 | -7.6 Million USD | 2.56% |
| 1996 Q1 | -7.8 Million USD | 0.0% |
| 1995 Q3 | -7.1 Million USD | -61.36% |
| 1995 Q4 | -7.8 Million USD | -9.86% |
| 1995 Q2 | -4.4 Million USD | -4.76% |
| 1995 Q1 | -4.2 Million USD | 27.59% |
| 1995 FY | -23.5 Million USD | 23.45% |
| 1994 Q4 | -5.8 Million USD | -45.0% |
| 1994 FY | -30.7 Million USD | 23.06% |
| 1994 Q1 | -10.7 Million USD | 6.96% |
| 1994 Q2 | -10.2 Million USD | 4.67% |
| 1994 Q3 | -4 Million USD | 60.78% |
| 1993 Q3 | -9.6 Million USD | -2.13% |
| 1993 Q2 | -9.4 Million USD | -1.08% |
| 1993 FY | -39.9 Million USD | -108.9% |
| 1993 Q1 | -9.3 Million USD | -45.31% |
| 1993 Q4 | -11.5 Million USD | -19.79% |
| 1992 Q1 | -3.3 Million USD | -57.14% |
| 1992 Q2 | -3.7 Million USD | -12.12% |
| 1992 Q3 | -5.8 Million USD | -56.76% |
| 1992 Q4 | -6.4 Million USD | -10.34% |
| 1992 FY | -19.1 Million USD | -324.44% |
| 1991 FY | -4.5 Million USD | -36.36% |
| 1991 Q4 | -2.1 Million USD | -133.33% |
| 1991 Q1 | - USD | 0.0% |
| 1991 Q3 | -900 Thousand USD | -200.0% |
| 1991 Q2 | -300 Thousand USD | 0.0% |
| 1990 Q3 | - USD | 0.0% |
| 1990 Q2 | - USD | 0.0% |
| 1990 Q1 | - USD | 0.0% |
| 1990 Q4 | - USD | 0.0% |
| 1990 FY | -3.3 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -146.39 Million USD | 2800.583% |
| Alkermes plc | 355.75 Million USD | -1011.32% |
| Agenus Inc. | -245.76 Million USD | 1708.717% |
| Aptorum Group Limited | -2.82 Million USD | 140067.932% |
| Ardelyx, Inc. | -66.06 Million USD | 6084.228% |
| Dyadic International, Inc. | -6.79 Million USD | 58280.012% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | 422493.162% |
| Lantern Pharma Inc. | -15.96 Million USD | 24869.549% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 20876.837% |
| Novavax, Inc. | -545.06 Million USD | 825.349% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 6882.289% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 5457.908% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 21417.695% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | 39691.428% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 6802.986% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 1158.159% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 16343.694% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 10688.109% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 2502.324% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 5490.268% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 19584.501% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 6450.655% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 12270.54% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 3084.007% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 998.052% |
| AlloVir, Inc. | -190.41 Million USD | 2176.274% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 2026.002% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 13995.684% |
| Bicycle Therapeutics plc | -180.66 Million USD | 2288.372% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 2308.061% |
| ChromaDex Corporation | -4.93 Million USD | 80164.804% |
| Chimerix, Inc. | -82.09 Million USD | 4915.884% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 8963.915% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 3973.42% |
| CRISPR Therapeutics AG | -153.61 Million USD | 2673.791% |
| Precision BioSciences, Inc. | -61.31 Million USD | 6547.594% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 2556.751% |
| Fortress Biotech, Inc. | -60.63 Million USD | 6620.111% |
| Fortress Biotech, Inc. | -60.63 Million USD | 6620.111% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 4946.286% |
| ImmuCell Corporation | -5.77 Million USD | 68565.372% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 3599.969% |
| Immix Biopharma, Inc. | -15.42 Million USD | 25729.377% |
| Incyte Corporation | 597.59 Million USD | -561.581% |
| Innoviva, Inc. | 179.72 Million USD | -2099.842% |
| IO Biotech, Inc. | -86.08 Million USD | 4692.777% |
| Jaguar Health, Inc. | -41.3 Million USD | 9672.881% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 2684.187% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | -7480.627% |
| ContextLogic Inc. | -317 Million USD | 1347.192% |
| MiMedx Group, Inc. | 67.43 Million USD | -5762.483% |
| MEI Pharma, Inc. | 17.77 Million USD | -22138.722% |
| NextCure, Inc. | -62.72 Million USD | 6403.27% |
| Onconetix, Inc. | -37.4 Million USD | 10668.384% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 10114.438% |
| Opthea Limited | -220.24 Million USD | 1895.115% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 7828.056% |
| Vaxcyte, Inc. | -402.26 Million USD | 1082.832% |
| PDS Biotechnology Corporation | -42.94 Million USD | 9306.795% |
| Precigen, Inc. | -95.9 Million USD | 4222.456% |
| Pharming Group N.V. | -10.54 Million USD | 37581.987% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 2061.189% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 16208.87% |
| PureTech Health plc | -65.69 Million USD | 6117.931% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 15857.044% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 1962.972% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 16343.694% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 1633.408% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 14615.016% |
| Acelyrin, Inc. | -381.64 Million USD | 1135.947% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | 31521248.972% |
| Summit Therapeutics Inc. | -614.92 Million USD | 742.937% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 11693.795% |
| Senti Biosciences, Inc. | -92.91 Million USD | 4354.889% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 3876.158% |
| Elevation Oncology, Inc. | -45.7 Million USD | 8750.446% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 11350.996% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | 30345.113% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | 59241.361% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 13565.023% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 46607.47% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 6974.272% |
| Seer, Inc. | -86.27 Million USD | 4682.45% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 6001.336% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 6111.708% |
| ESSA Pharma Inc. | -26.58 Million USD | 14973.031% |
| GlycoMimetics, Inc. | -36.89 Million USD | 10814.532% |
| GT Biopharma, Inc. | -7.59 Million USD | 52141.595% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 1738.044% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | 7714.059% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | -5436.479% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 7364.709% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 8148.86% |
| Alzamend Neuro, Inc. | -9.94 Million USD | 39843.677% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 790.172% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | 110289.521% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 7843.351% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 1709.805% |
| Aptose Biosciences Inc. | -51.2 Million USD | 7820.819% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 4122.058% |
| Soligenix, Inc. | -6.14 Million USD | 64483.225% |
| Century Therapeutics, Inc. | -136.67 Million USD | 2992.744% |
| Kura Oncology, Inc. | -152.63 Million USD | 2690.299% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 4531.393% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | 37617.556% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | -699070.601% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | 694933.04% |
| Autolus Therapeutics plc | -208.38 Million USD | 1997.276% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 5598.901% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 5684.575% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 18346.262% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 1855.205% |
| GRI Bio, Inc. | -13.03 Million USD | 30425.995% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | 95722.818% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 3286.229% |
| IGM Biosciences, Inc. | -246.41 Million USD | 1704.441% |
| INmune Bio, Inc. | -30 Million USD | 13275.153% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 3676.009% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 9470.1% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 24869.357% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 25130.733% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 6724.11% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 4007.994% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 1531.81% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 1761.931% |
| Verastem, Inc. | -87.36 Million USD | 4625.278% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 7396.08% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 2550.538% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 3489.052% |
| Histogen Inc. | -10.62 Million USD | 37324.367% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 27773.182% |
| Surrozen, Inc. | -43.04 Million USD | 9285.447% |
| Organovo Holdings, Inc. | -14.67 Million USD | 27048.402% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 77819.235% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 7653.838% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 15749.764% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 14776.665% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | 47408.356% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 2716.805% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 8180.768% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 13400.589% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | 38050.781% |
| Apollomics, Inc. | -172.6 Million USD | 2390.601% |
| Amarin Corporation plc | -59.11 Million USD | 6788.32% |
| Mesoblast Limited | -87.95 Million USD | 4594.975% |
| Turnstone Biologics Corp. | -55.2 Million USD | 7262.319% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 2790.219% |
| Synaptogenix, Inc. | -6.03 Million USD | 65573.17% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 24492.892% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 5167.419% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 82613.369% |
| Monopar Therapeutics Inc. | -8.4 Million USD | 47154.365% |
| Exelixis, Inc. | 207.76 Million USD | -1802.919% |
| Better Therapeutics, Inc. | -39.76 Million USD | 10043.662% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 2846.547% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 847.898% |
| NLS Pharmaceutics AG | -12.17 Million USD | 32581.027% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | 50821.709% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 12957.654% |
| Gritstone bio, Inc. | -138.49 Million USD | 2954.791% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 6232.94% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 98941.236% |
| Avid Bioservices, Inc. | -140.75 Million USD | 2908.892% |
| Insmed Incorporated | -749.56 Million USD | 627.451% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 26128.493% |
| MediWound Ltd. | -6.71 Million USD | 58968.374% |
| OmniAb, Inc. | -50.61 Million USD | 7910.506% |
| Alector, Inc. | -130.39 Million USD | 3132.111% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 3576.487% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 7725.514% |
| Zai Lab Limited | -334.62 Million USD | 1281.519% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 1320.3% |
| Aura Biosciences, Inc. | -76.4 Million USD | 5274.327% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 1785.022% |
| Immunic, Inc. | -93.61 Million USD | 4323.39% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 3009.348% |
| Veracyte, Inc. | -74.4 Million USD | 5413.693% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | 51609.012% |
| FibroGen, Inc. | -284.23 Million USD | 1490.976% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 15171.668% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 56564.755% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 21093.279% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | -853.061% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 17628.708% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | -7924.193% |
| TG Therapeutics, Inc. | 12.67 Million USD | -31099.495% |
| Galecto, Inc. | -38.34 Million USD | 10409.526% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 21056.218% |
| Fortrea Holdings Inc. | -3.4 Million USD | 116382.353% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 3221.822% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 22807.484% |
| XBiotech Inc. | -24.55 Million USD | 16199.686% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 6232.94% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 6407.594% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 4116.825% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 18551.486% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 7263.227% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 751.722% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 5892.396% |
| Vaxxinity, Inc. | -56.93 Thousand USD | 6944280.981% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 1845.218% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 17855.008% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 1899.463% |
| NexImmune, Inc. | -32.34 Million USD | 12323.448% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | 74885.674% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 28247.726% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 16423.025% |
| Scopus BioPharma Inc. | -11.6 Million USD | 34153.91% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 3484.989% |
| Ainos, Inc. | -13.77 Million USD | 28810.547% |
| Pluri Inc. | -20.88 Million USD | 19027.614% |
| Prothena Corporation plc | -147.02 Million USD | 2789.012% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 3571.999% |
| Celularity Inc. | -196.29 Million USD | 2114.111% |
| Rallybio Corporation | -74.56 Million USD | 5402.291% |
| Cue Biopharma, Inc. | -50.73 Million USD | 7892.955% |
| MeiraGTx Holdings plc | -84.02 Million USD | 4805.154% |
| Omeros Corporation | -117.81 Million USD | 3455.827% |
| Humacyte, Inc. | -110.77 Million USD | 3669.004% |
| Immunocore Holdings plc | -55.28 Million USD | 7251.048% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 22083.986% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 17341.289% |
| Blueprint Medicines Corporation | -506.98 Million USD | 879.827% |
| CalciMedica, Inc. | -34.35 Million USD | 11607.408% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 5942.039% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 2895.941% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 2484.718% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 1495.774% |
| Pulmatrix, Inc. | -14.12 Million USD | 28098.017% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 11333.414% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 4884.24% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 921.626% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 3869.965% |
| Cytokinetics, Incorporated | -526.24 Million USD | 851.286% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 11062.429% |
| Nutriband Inc. | -5.48 Million USD | 72176.093% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 9881.296% |
| Vor Biopharma Inc. | -117.86 Million USD | 3454.403% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 9.09% |
| Evogene Ltd. | -23.87 Million USD | 16656.807% |
| ProKidney Corp. | -35.46 Million USD | 11246.949% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 3401.187% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | 50493.926% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 714.675% |
| CorMedix Inc. | -46.33 Million USD | 8631.864% |
| BioLineRx Ltd. | -60.61 Million USD | 6622.586% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 3985.831% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 9727.429% |
| Atai Life Sciences N.V. | -40.22 Million USD | 9928.958% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 5002.159% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 5335.1% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 1453.088% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 14282.81% |
| MediciNova, Inc. | -8.57 Million USD | 46224.863% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 3307.086% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 47296.829% |
| GeoVax Labs, Inc. | -25.96 Million USD | 15325.618% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 1752.58% |
| Biomea Fusion, Inc. | -117.25 Million USD | 3471.797% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 730.957% |
| Mereo BioPharma Group plc | -29.46 Million USD | 13517.498% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 2681.319% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 1988.422% |
| Absci Corporation | -110.56 Million USD | 3675.783% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 13213.101% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 4020.783% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 1775.702% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | -27971.571% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 2148.901% |
| Allakos Inc. | -185.7 Million USD | 2229.014% |
| Imunon, Inc. | -19.51 Million USD | 20359.312% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 4161.848% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -3624.892% |
| BioAtla, Inc. | -123.46 Million USD | 3302.281% |
| NLS Pharmaceutics AG | -12.17 Million USD | 32581.027% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 24690.123% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 1308.073% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 10800.154% |
| XOMA Corporation | -40.83 Million USD | 9782.839% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 3981.025% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 3436.005% |
| aTyr Pharma, Inc. | -50.38 Million USD | 7946.157% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 4609.176% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 2705.183% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 1763.035% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 11357.724% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | 48958.494% |
| Akari Therapeutics, Plc | -10 Million USD | 39604.396% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 5872509.952% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | -1304.007% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 59419.729% |
| UroGen Pharma Ltd. | -102.24 Million USD | 3966.828% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 3802.115% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 50935.881% |
| Orgenesis Inc. | -55.36 Million USD | 7241.489% |
| Entera Bio Ltd. | -8.88 Million USD | 44577.444% |
| GH Research PLC | -35.58 Million USD | 11209.675% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 19071.209% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 5208.802% |
| Xencor, Inc. | -126.08 Million USD | 3235.613% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | 105089.72% |
| Replimune Group, Inc. | -215.79 Million USD | 1932.118% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 18690.709% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | -157476.724% |
| Lexaria Bioscience Corp. | -6.66 Million USD | 59419.729% |
| Portage Biotech Inc. | -75.33 Million USD | 5347.747% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 47296.829% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 4190.425% |
| OncoCyte Corporation | -27.78 Million USD | 14331.309% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | 29566.628% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | 35649.098% |
| Purple Biotech Ltd. | -19.88 Million USD | 19987.324% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | 56427.112% |
| scPharmaceuticals Inc. | -54.81 Million USD | 7313.282% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 22684.074% |
| HilleVax, Inc. | -123.56 Million USD | 3299.586% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | 39217.443% |
| Tharimmune, Inc. | -9.31 Million USD | 42524.725% |
| Genprex, Inc. | -30.86 Million USD | 12911.215% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 1775.787% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 13237.502% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | 221963.075% |
| Virios Therapeutics, Inc. | -5.29 Million USD | 74752.357% |
| OKYO Pharma Limited | -16.82 Thousand USD | 23497823.093% |
| Savara Inc. | -54.69 Million USD | 7328.052% |
| Curis, Inc. | -47.41 Million USD | 8438.641% |
| Daré Bioscience, Inc. | -30.16 Million USD | 13208.149% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 25697.784% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | 71092.997% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 13360.439% |
| BeiGene, Ltd. | -881.7 Million USD | 548.402% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 18666.732% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 1006.026% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 5107.409% |
| Erasca, Inc. | -125.04 Million USD | 3261.818% |
| bluebird bio, Inc. | -211.91 Million USD | 1965.671% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 79164.141% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -2258.317% |
| DBV Technologies S.A. | -72.72 Million USD | 5536.295% |
| Protagenic Therapeutics, Inc. | -5 Million USD | 79164.141% |
| Moderna, Inc. | -4.71 Billion USD | 183.869% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 9945.357% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | 69534.492% |
| Molecular Templates, Inc. | -8.12 Million USD | 48765.682% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 6646.996% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 3649.044% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 3020.976% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 8350.59% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 2895.466% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 2154.779% |
| MacroGenics, Inc. | -9.05 Million USD | 43747.604% |
| RenovoRx, Inc. | -10.23 Million USD | 38739.562% |
| Adicet Bio, Inc. | -142.65 Million USD | 2871.383% |
| Prime Medicine, Inc. | -198.13 Million USD | 2095.427% |
| Aditxt, Inc. | -32.38 Million USD | 12309.69% |
| Adagene Inc. | -18.94 Million USD | 20967.322% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 54172.07% |
| Quantum-Si incorporated | -95.96 Million USD | 4220.05% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 3421.543% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 27220.75% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | -2887.682% |
| SciSparc Ltd. | -5.12 Million USD | 77288.598% |
| Vericel Corporation | -3.18 Million USD | 124348.9% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 3287807.685% |
| Minerva Neurosciences, Inc. | -30 Million USD | 13276.316% |
| Generation Bio Co. | -126.61 Million USD | 3222.611% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 5523.989% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 4895.614% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 1608.202% |
| Invivyd, Inc. | -198.64 Million USD | 2090.304% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 1256.115% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | 45613.921% |
| Spero Therapeutics, Inc. | 22.8 Million USD | -17235.789% |
| Artelo Biosciences, Inc. | -9.87 Million USD | 40140.51% |
| 2seventy bio, Inc. | -217.57 Million USD | 1917.162% |
| ADMA Biologics, Inc. | -28.23 Million USD | 14100.496% |
| Clene Inc. | -49.5 Million USD | 8086.425% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 17839.058% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 8097.734% |
| GeoVax Labs, Inc. | -25.96 Million USD | 15325.618% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 1305.123% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 12248.882% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | -17301.408% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 4101.954% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 5388.814% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 2558.63% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 742.798% |
| Evaxion Biotech A/S | -22.12 Million USD | 17969.379% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 4996.948% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 2076.128% |
| Trevena, Inc. | -40.28 Million USD | 9913.1% |
| Surrozen, Inc. | -43.04 Million USD | 9285.447% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 5818.749% |
| Cingulate Inc. | -23.53 Million USD | 16898.848% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | 57299.074% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 10018.716% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | 51374.383% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 4482.663% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 6551.065% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 6744.371% |
| Clearmind Medicine Inc. | -11.95 Million USD | 33170.596% |
| Kronos Bio, Inc. | -112.67 Million USD | 3608.915% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 5813.542% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 155885015.8% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 4702.829% |
| Statera Biopharma, Inc. | -174.4 Million USD | 2366.866% |
| ImmunityBio, Inc. | -583.19 Million USD | 777.92% |
| Korro Bio, Inc. | -81.17 Million USD | 4970.645% |
| Kineta, Inc. | -14.09 Million USD | 28141.705% |
| BioVie Inc. | -32.12 Million USD | 12408.638% |
| Codexis, Inc. | -76.24 Million USD | 5285.729% |
| Celularity Inc. | -196.29 Million USD | 2114.111% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 1942.921% |
| Celcuity Inc. | -63.77 Million USD | 6298.894% |
| Virax Biolabs Group Limited | -6.73 Million USD | 58815.056% |
| Cibus, Inc. | -267.62 Million USD | 1577.28% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 9904.097% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 11140.183% |
| IN8bio, Inc. | -30 Million USD | 13275.592% |
| Kodiak Sciences Inc. | -260.49 Million USD | 1617.749% |
| Annexon, Inc. | -134.23 Million USD | 3045.239% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 3474.387% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 6557.176% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 12633.604% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 1179.375% |
| Eyenovia, Inc. | -27.26 Million USD | 14602.718% |
| Puma Biotechnology, Inc. | 21.59 Million USD | -18211.333% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 739090.654% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 5274.598% |
| Arcellx, Inc. | -70.69 Million USD | 5692.87% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 9640.31% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 3054.505% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 13262.433% |
| Moolec Science SA | -51.78 Million USD | 7734.071% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 7649.216% |
| Geron Corporation | -184.12 Million USD | 2247.214% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 9519.164% |
| Royalty Pharma plc | 1.13 Billion USD | -248.386% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 3008.0% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | 44563.423% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 18711.105% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 2403.023% |
| Humacyte, Inc. | -110.77 Million USD | 3669.004% |
| Structure Therapeutics Inc. | -89.62 Million USD | 4511.515% |
| 89bio, Inc. | -142.18 Million USD | 2880.525% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 5833.179% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | 38199.643% |
| Genelux Corporation | -28.29 Million USD | 14071.799% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 13702.615% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 2332.172% |
| Notable Labs, Ltd. | -11.26 Million USD | 35199.432% |
| Liquidia Corporation | -78.5 Million USD | 5136.305% |
| Mustang Bio, Inc. | -51.6 Million USD | 7761.719% |
| Immunovant, Inc. | -259.33 Million USD | 1624.509% |
| Quantum-Si incorporated | -95.96 Million USD | 4220.05% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 5527.116% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 20499.36% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 4218.762% |
| Acasti Pharma Inc. | -12.85 Million USD | 30860.134% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 17704.528% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 24869.357% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 2267.627% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | 92011.76% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | 31804.892% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 13506.124% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 10240.556% |
| PepGen Inc. | -78.62 Million USD | 5128.362% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 13380.93% |
| United Therapeutics Corporation | 984.8 Million USD | -301.462% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 17861.006% |
| Solid Biosciences Inc. | -96.01 Million USD | 4217.69% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 82613.369% |
| Immuneering Corporation | -53.47 Million USD | 7493.828% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | 77819.235% |
| Silo Pharma, Inc. | -3.7 Million USD | 106934.333% |
| Belite Bio, Inc | -31.63 Million USD | 12598.735% |
| XOMA Corporation | -40.83 Million USD | 9782.839% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 7372.326% |
| Bionomics Limited | -15.49 Billion USD | 125.52% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 4807.507% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 13659.694% |
| uniQure N.V. | -308.47 Million USD | 1381.647% |
| Cassava Sciences, Inc. | -97.21 Million USD | 4166.778% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 54172.07% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 3303.111% |
| Forte Biosciences, Inc. | -31.47 Million USD | 12660.681% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | 48304.623% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 13701.211% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | 739090.654% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 15171.668% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 24083.015% |
| Altimmune, Inc. | -88.44 Million USD | 4570.022% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 2708.191% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 13659.694% |
| Compugen Ltd. | -18.75 Million USD | 21181.369% |
| Peak Bio, Inc. | -1259.26 USD | 313962268.258% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 8685.637% |
| Benitec Biopharma Inc. | -21.75 Million USD | 18276.636% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 1266.977% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 4866.015% |
| Zura Bio Limited | -60.36 Million USD | 6650.033% |
| PolyPid Ltd. | -23.86 Million USD | 16666.52% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 25230.943% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 4866.015% |
| Instil Bio, Inc. | -156.08 Million USD | 2632.946% |
| argenx SE | -295.05 Million USD | 1439.963% |
| Immunome, Inc. | -106.8 Million USD | 3801.665% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 9403.902% |
| Verona Pharma plc | -54.36 Million USD | 7371.791% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 4056.884% |
| Shattuck Labs, Inc. | -87.29 Million USD | 4628.855% |
| CervoMed Inc. | -2.17 Million USD | 182136.427% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 3271.735% |
| Plus Therapeutics, Inc. | -13.31 Million USD | 29790.598% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 9177.259% |
| Moolec Science SA | -51.78 Million USD | 7734.071% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | 22864209.028% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 3026.049% |
| AnaptysBio, Inc. | -163.61 Million USD | 2516.345% |
| Design Therapeutics, Inc. | -66.86 Million USD | 6013.075% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 4956.167% |
| NeurAxis, Inc. | -14.62 Million USD | 27130.052% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 10536.619% |
| Lumos Pharma, Inc. | -34.03 Million USD | 11716.619% |
| Achilles Therapeutics plc | -69.66 Million USD | 5775.16% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 4056.884% |
| 180 Life Sciences Corp. | -19.93 Million USD | 19932.344% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | -131301.66% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | 155885015.8% |
| Nutriband Inc. | -5.48 Million USD | 72176.093% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 4026.234% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 8233.808% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 5228.485% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 11738.505% |
| MoonLake Immunotherapeutics | -36 Million USD | 11080.008% |
| Palisade Bio, Inc. | -12.3 Million USD | 32243.089% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 9485.623% |
| Beam Therapeutics Inc. | -132.52 Million USD | 3083.241% |
| Neurogene Inc. | -36.31 Million USD | 10986.362% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 2519.362% |
| AEON Biopharma, Inc. | -52.55 Million USD | 7622.643% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 4128.243% |
| Sesen Bio, Inc. | -19.88 Million USD | 19983.323% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 5623.022% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | 31693.678% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 990.376% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 3643.732% |
| Athira Pharma, Inc. | -117.67 Million USD | 3459.848% |
| Vaccinex, Inc. | -20.25 Million USD | 19622.987% |
| HCW Biologics Inc. | -24.99 Million USD | 15918.021% |
| XOMA Corporation | -40.83 Million USD | 9782.839% |
| Nektar Therapeutics | -276.05 Million USD | 1532.173% |
| Arvinas, Inc. | -367.3 Million USD | 1176.395% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | 5872509.952% |
| Merus N.V. | -154.93 Million USD | 2651.714% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 4157.971% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 12697.101% |
| Rezolute, Inc. | -68.45 Million USD | 5875.135% |
| Clene Inc. | -49.5 Million USD | 8086.425% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 25733.659% |
| BeyondSpring Inc. | -21.02 Million USD | 18903.386% |
| Synlogic, Inc. | -57.28 Million USD | 7001.994% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | 33320.738% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 36619.49% |
| Peak Bio, Inc. | -1259.26 USD | 313962268.258% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 10680.176% |
| Krystal Biotech, Inc. | 10.93 Million USD | -36065.386% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 2862.843% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 1316.103% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | 85694.933% |
| MannKind Corporation | -11.93 Million USD | 33217.775% |
| Ikena Oncology, Inc. | -68.16 Million USD | 5899.959% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 18913.229% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 4354.248% |
| Gossamer Bio, Inc. | -179.81 Million USD | 2298.68% |
| CohBar, Inc. | -11.96 Million USD | 33151.0% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 15431.162% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 13213.101% |
| Legend Biotech Corporation | -518.25 Million USD | 862.869% |
| Mural Oncology plc | -207.44 Million USD | 2005.836% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 3285.433% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 21716.509% |
| Disc Medicine, Inc. | -76.42 Million USD | 5272.906% |
| Champions Oncology, Inc. | -7.27 Million USD | 54437.548% |
| REGENXBIO Inc. | -263.49 Million USD | 1600.452% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | 37352.167% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 8422.492% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 10508.731% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 4047.166% |
| Vaxart, Inc. | -82.46 Million USD | 4894.276% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | -1184453.111% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 10630.995% |
| Cellectis S.A. | -101.05 Million USD | 4012.17% |
| Longeveron Inc. | -21.41 Million USD | 18563.55% |
| Repare Therapeutics Inc. | -93.79 Million USD | 4315.105% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 837.644% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 5655.228% |
| Revolution Medicines, Inc. | -436.36 Million USD | 1006.026% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | 60267.402% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 12926.369% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 5802.335% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 6207.644% |
| Anixa Biosciences, Inc. | -9.81 Million USD | 40397.625% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | -9.228% |
| Denali Therapeutics Inc. | -145.22 Million USD | 2822.415% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | 3287807.685% |
| Veru Inc. | -93.15 Million USD | 4344.214% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 14727.252% |
| Cingulate Inc. | -23.53 Million USD | 16898.848% |
| Passage Bio, Inc. | -102.06 Million USD | 3973.724% |
| Context Therapeutics Inc. | -23.96 Million USD | 16597.935% |
| Exicure, Inc. | -16.91 Million USD | 23474.719% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 2192.771% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 10569.23% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | 60856.153% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 2240.807% |
| Nuvalent, Inc. | -126.21 Million USD | 3232.333% |
| ABVC BioPharma, Inc. | -10.51 Million USD | 37697.274% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 4650.697% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 13043.95% |
| OmniAb, Inc. | -50.61 Million USD | 7910.506% |
| Anew Medical, Inc. | 1.34 Million USD | -293602.294% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 24740.698% |
| Lipocine Inc. | -16.35 Million USD | 24277.961% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 6054.755% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 6309.03% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 9470.1% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 8342.333% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 20036.463% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 830.135% |
| Ocugen, Inc. | -63.07 Million USD | 6367.795% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 4229.863% |
| Q32 Bio Inc. | -112.96 Million USD | 3599.969% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 23096.743% |
| Alumis Inc. Common Stock | -154.99 Million USD | 2650.825% |
| Equillium, Inc. | -13.33 Million USD | 29748.294% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 6649.382% |
| Coya Therapeutics, Inc. | -7.98 Million USD | 49595.258% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 21072.641% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 6791.717% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 3552.112% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 21612.732% |
| Dominari Holdings Inc. | -22.88 Million USD | 17378.21% |
| Edesa Biotech, Inc. | -8.37 Million USD | 47310.462% |
| vTv Therapeutics Inc. | -20.25 Million USD | 19623.951% |
| Bio-Techne Corporation | 168.1 Million USD | -2251.863% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 1222.901% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | -2968.303% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 3345.124% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 10520.939% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 3609.881% |
| Nkarta, Inc. | -117.5 Million USD | 3464.737% |
| BioCardia, Inc. | -11.57 Million USD | 34268.179% |
| Iterum Therapeutics plc | -38.37 Million USD | 10403.615% |